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The central theme of my research has consistently been to investigate mechanisms 
that control proliferation and differentiation with emphasis on regulation that is compro-
mised in cancer. Starting as a graduate student, I have been committed to exploring cell 
cycle and growth control and tissue-specific transcription. And, I have been fortunate, 
throughout my career, to have colleagues who nurtured an architectural perspective of 
gene expression providing a novel dimension to the problem from both fundamental 
biological and clinical perspectives.
It was a unique opportunity to contribute to the initial characterization of transcrip-
tional regulation that mediates control of the cell cycle. The studies from our laboratory 
in the early 1970s provided insight into the molecular mechanisms regulating gene 
expression during the cell cycle at the G1/S phase transition in normal and tumor cells. To 
mechanistically examine linkages between proliferation and differentiation we developed 
a foundation for addressing bone tissue-specific gene expression. Our research group has 
established aberrations that accompany the onset and progression of skeletal disease and 
changes in gene expression that are associated with breast and prostate tumor metastasis to 
bone. A major contribution from our laboratory has been to mechanistically define func-
tional relationships between the subnuclear organization of nucleic acids and regulatory 
proteins. During the past several years our research group has focused on combinatorial 
organization and assembly of regulatory machinery for gene expression in nuclear micro-
environments for epigenetic control of cell fate and lineage commitment in biological 
control and cancer. 
Progress in science does not occur in a vacuum. For me, the longstanding partner-
ships with Janet Stein, Jane Lian, Andre van Wijnen and Martin Montecino have been 
both effective and exceptionally meaningful. These are gifted scientists with skill sets and 
perspectives that have provided a broad-based platform to confront the challenges of 
growth control and tissue-specific gene expression that is compromised in cancer. Janet 
is an outstanding nucleic acid biochemist. Jane is a highly talented bone biologist, Andre 
is an innovative molecular biologist and Martin is an insightful chromatin biochemist. It 
is gratifying to look back at decades of collaboration and describe “our,” rather than my 
initiatives and contributions.
I never lose sight of the mentors and collaborators who have been truly instrumental 
in development of strategies and experimental approaches. Sheldon Penman, since the late 
1960s, has been the driving force behind pursuit of cell structure-gene expression relation-
ships. Arthur Pardee, Renato Baserga and my thesis advisor Howard Rothstein guided our 
investigations into the regulatory mechanisms that are operative in cell cycle control; not 
simply as components of pathways but within the context of physiologically integrated 
networks and regulatory machinery that is dynamically organized and assembled. Art 
Pardee had the vision to dissect the components of combinatorial control and recognized 
the importance of multi-dimensional signaling mechanisms. 
A collaboration with Carlo Croce over many years has provided a cancer genetic 
perspective. Sidney Weinhouse taught me the importance of relating biochemical and 
molecular mechanisms to cancer as a disease. His guidance solidified my commitment to 
tumor biology and pathology. A rewarding partnership and friendship with our Cancer 
Center Director, Dario Altieri, to build a Cancer Center with disease-based programs 
where tumor biology and pathology are pursued in a seamless manner, has been profes-
sionally and personally rewarding.
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characterization of tranScriptional reGulation that 
mediateS cell cycle control
In the mid to late 1960s as a graduate student at the University 
of Vermont, working with Howard Rothstein, I initiated studying 
cell cycle control using early cleavage divisions of the zebrafish 
Brachydanio rerio and wound healing in lens epithelial cells as 
models. At that time, recombinant DNA technology had not been 
developed and the field of eukaryotic gene expression was in its 
infancy. Although interpretation of cell cycle regulatory mechanisms 
was dependent upon results from metabolic labeling and inhibitor 
studies, we made a series of observations that directed our focus 
to the G1/S phase cell cycle transition.
1-4 With the demonstration 
by Hewson Swift and Ted Borun that histone protein synthesis is 
restricted to the S phase of the cell cycle, we developed control of 
histone gene expression as a paradigm for defining transcriptional 
regulatory mechanisms that are operative at the onset of S phase. 
During the past forty years we have made a series of contributions to 
understanding cell cycle and growth control that have impacted on 
fundamental regulatory mechanisms that support proliferation and 
directly relate to aberrant gene expression in cancer. By the combined 
application of in vivo and in vitro experimental approaches that 
include biochemical, molecular, cellular and in vivo genetic analysis, 
we have been utilizing the histone gene promoter to identify and 
characterize the requirements for transcriptional competency at the 
G1/S phase transition point in response to factors that combina-
torially regulate cell cycle progression and mechanisms that couple 
histone gene expression with DNA replication.5-9
We were one of the first laboratories to establish that tran-
scriptional control is a key regulatory mechanism mediating the 
G1/S phase cell cycle transition. We demonstrated that transcription 
factors modulate control of gene expression in a cell cycle dependent 
manner.2 Subsequently, we cloned the first human cell cycle regu-
latory genes and used them to probe for proliferation-dependent 
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signaling pathways operative at the onset of S phase.10,11 These 
studies uncovered principal regulatory mechanisms that temporarily 
and functionally couple expression of multiple histone genes with 
DNA replication. We made the initial observation that remodeling 
of chromatin structure and nucleosome organization supports modi-
fications in transcription for cell cycle progression.12 This pursuit 
of nuclear organization as a component of transcriptional control 
provided us with an orientation that continues to guide our experi-
mental strategies. 
In collaboration with Lewis Kleinsmith our laboratory provided 
the initial observation that phosphorylation of transcription factors is 
a key component of cell cycle-related gene expression.3 We identified 
a series of cell cycle regulatory elements and cognate transcription 
factor complexes that are responsible for upregulation of gene expres-
sion at the G1/S phase transition. These studies have defined a novel 
cell cycle checkpoint at the initiation of S phase that is E2F indepen-
dent as well as temporally, biochemically and functionally distinct 
from the R point late in G1 when genes encoding enzymes for 
deoxynucleotide metabolism are upregulated (e.g. thymidine kinase, 
dihydrofolate reductase). We have characterized “R-point–S phase” 
signaling mechanisms.13,14 Our research group has shown that regu-
latory factor complexes that mediate transcriptional control at the 
G1/S phase transition are stringently cell cycle regulated in normal 
cells and constitutive in transformed and tumor cells where growth 
control has been abrogated.15,16 The experimental approaches we 
employed included cell free systems, intact cell studies, gene expres-
sion profiling at the G1/S phase transition and the first transgenic 
animal models for transcriptional control of cell cycle regulated 
genes.6 An early lesson we learned is the necessity to pursue multi-
disciplinary approaches to address the challenges of combinatorial 
complexity that is operative in biological control.
Gene expreSSion controllinG SKeletal proliferation 
and differentiation and Bone cancer
For many years our laboratory, to a large extent due to the insight 
and dedication of Jane Lian, has been actively engaged in defining 
molecular, cellular, biochemical, genetic and physiological mecha-
nisms that regulate skeletal development and bone remodeling in 
vitro and in vivo. We have focused on skeletal pathology and tumors 
that originate in bone or preferentially interact with the bone micro-
environment. Metastatic breast and prostate tumors are the two 
bone-seeking tumors that we have been examining. 
Our laboratory was fortunate to be in a position to provide 
concepts and experimental approaches that have paved the 
way for resolving complexities of regulatory mechanisms that 
control osteoblast proliferation and differentiation including the 
identification of steroid hormone responsive promoter elements 
and bone tissue-specific transcription factors and coregulatory 
complexes.15,17-20 A breakthrough for us to understand bone cell 
biology and pathology was the identification of distinct develop-
mental stages (i.e. proliferation, extracellular matrix maturation, 
extracellular matrix mineralization and apoptosis) that reflect estab-
lishment and maintenance of the osteoblast phenotype. Our research 
group laid the foundation for addressing gene regulatory mechanisms 
that are operative during development of the osteoblast phenotype by 
characterizing the promoters of cell growth and bone specific genes as 
blueprints for responsiveness to physiological regulatory signals. We 
established osteoblast phenotype development as a widely utilized 
approach for studying signaling mechanisms operative during osteo-
blast differentiation, as well as for examining selective responsiveness 
to physiological and pharmacological mediators at specific stages of 
bone cell maturation. Our research team was the first to characterize 
perturbations in osteoblast growth and differentiation in vivo in 
rodent models of bone metabolic disease (osteoporosis and osteo-
petrosis) and cancer (osteosarcoma).16 The sequential stages and 
developmental transitions of osteoblast maturation have proved to be 
a paradigm for many investigators to define regulatory parameters of 
bone biology and pathology. 
To bridge the gap between regulatory mechanisms and clinical 
applications, our laboratory has developed a novel, transplantation-
based approach for targeting gene therapy to bone using tissue-specific 
promoters. The combined insights obtained from characterizing 
bone-specific regulatory mechanisms in culture, in transgenic mice 
and in rodent knockout models, as well as in bone marrow-derived 
osteoblast precursor cells have permitted development of novel 
approaches for targeting gene therapy to bone using tissue-specific 
promoters.21
Building on our earlier observations that chromatin structure 
and nucleosome organization are dynamically modified to accom-
modate expression of genes during the cell cycle we demonstrated 
that chromatin remodeling of skeletal genes supports bone tissue-
specific and steroid hormone-responsive transcription. With Martin 
Montecino, initially as a graduate student in our laboratory and now 
as a Professor at the University of Concepcion in Chile, we pioneered 
understanding of interrelationships between nuclear architecture 
and control of skeletal gene expression supporting bone cell differ-
entiation. We have functionally linked remodeling of the chromatin 
structure and nucleosome organization of skeletal gene promoters 
with competency for interactions with physiologic mediators of 
transcription.18,22 
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nuclear microenvironmentS 
Our pursuit of mechanisms that control proliferation and 
differentiation have been guided by the requirement to understand 
localization of regulatory complexes within the nucleus where 
the combinatorial components of gene expression are organized, 
assembled and integrated. Our appreciation for the role of nuclear 
organization in control of gene expression, particularly in relation 
to biological control and cancer has evolved during the past several 
years. There is recognition that extensive informational content is 
encoded in epigenetic signatures that go beyond DNA sequences. 
DNA methylation and histone modifications are providing signatures 
for epigenetic control of proliferation, differentiation, transformation 
and tumor progression as components of mechanisms that sustain 
aberrant gene expression. 
We have been addressing regulatory parameters of transcrip-
tion that are related to localization of nucleic acids and regulatory 
proteins within the cell nucleus. Relationships between nuclear 
structure and gene expression have been recognized for some time. 
Nucleoli are focal sites where the regulatory machinery for ribosomal 
gene expression resides. Functional compartmentalization of the 
cell nucleus is reflected by intranuclear sites that are dedicated to 
replication, repair, cell survival, and RNA processing. The changes 
in nuclear morphology that occur during hematopoietic cell differ-
entiation are striking and reflect modifications in the organization of 
nucleic acids and regulatory proteins that support biological control. 
Transformation and tumor progression are frequently associated with 
altered nuclear organization. However, the challenge is to mechanis-
tically understand the localization of regulatory complexes within 
the cell nucleus using criteria that are specific and quantitative. Our 
objective has been to develop regulatory parameters of nuclear orga-
nization into targets for tumor diagnosis and therapy.
Our group is actively engaged in exploring the intranuclear 
organization of regulatory domains with emphasis on modifications 
in cancer cells. Our strategy has been directed to the AML/Runx 
transcription factors that support tissue-specific gene expression 
(AML1 supports hematopoiesis, Runx2/AML3 supports osteogen-
esis and Runx3/AML2 supports gastrointestinal cell differentiation) 
and context-dependent tumor suppression. We have focused on two 
classes of nuclear microenvironments that mediate organization, 
assembly and integration of regulatory cues. First, we established that 
the Runx transcription factors bind to multiple sites of target gene 
promoters where they are strategically placed to scaffold coregula-
tory proteins for epigenetic control and serve as endpoints for key 
signaling pathways. Here, the regulatory signal is the Runx DNA 
binding domain. Second, we are pursuing a novel dimension to 
genetic and epigenetic control by intranuclear trafficking.23,24 An 
initial component of a mechanism for localization of regulatory 
complexes within the nucleus came from our identification of a 
unique 31 amino acid intranuclear trafficking sequence which func-
tions autonomously. Specificity of the Runx intranuclear trafficking 
signal is supported by a unique sequence and a unique crystal struc-
ture. To quantitatively define a signature for positioning of Runx 
regulatory proteins within the nucleus we developed a strategy that 
combines high resolution quantitative image processing with point 
mutations in Runx proteins that are determinants for temporal, 
spatial and functional parameters of control. Using emerging capabil-
ities of high resolution imaging, we have quantitatively constructed 
signatures for colocalization of Runx regulatory proteins within 
the nucleus that reflect the transformed phenotype.24-26 We have 
demonstrated that the T(8;21) chromosomal translocation in AML 
leukemia disrupts the AML locus and results in aberrant intranuclear 
trafficking of AML transcription factors that compromise fidelity 
of tissue-specific gene expression. Our research group has further 
linked intranuclear trafficking of transcription factors with activity of 
tissue-specific genes using in vitro and in vivo genetic approaches. We 
have demonstrated that cancer cells exhibit altered subnuclear distri-
bution of transcription factors supporting linkage of compromised 
intranuclear trafficking with tumorigenesis. We showed that replace-
ment of the chromosome 21 encoded intranuclear trafficking signal 
in the AML transcription factors as a consequence of chromosomal 
translocation that occurs frequently in AML leukemia, redirects a 
major hematopoietic regulatory protein to sites within the nucleus 
for transcriptional suppression rather than activation. These findings 
provide evidence that subnuclear localization of regulatory proteins is 
linked with formation of osteolytic lesions by metastatic breast cancer 
cells and the leukemic phenotype.
Recent efforts in our laboratory have been directed to the extent 
that microenvironments with transcriptional regulatory machinery 
contribute to epigenetic control. We have been focusing on Runx/
AML transcription factors and leukemia-related Runx/AML translo-
cation-fusion proteins in parental and post mitotic progeny cells to 
investigate mechanistic parameters of cell fate and lineage commit-
ment. We have observed that the wild type and translocation/fusion 
Runx/AML transcription factors are retained at chromosomal loci 
during mitosis providing a novel dimension to epigenetic retention 
of phenotypic gene expression for biological control. An analogous 
mechanism appears to be operative that sustains the transformed and 
tumor phenotypes of cancer cells and similar mechanisms epigeneti-
cally support cell fate, lineage commitment and coordinate control 
of proliferation, cell growth and tissue specific gene expression in a 
broad biological context.27,28
collaBoration iS Key to curinG cancer
Collective insight into regulatory parameters that govern biolog-
ical control of proliferation and differentiation and perturbations 
that are associated with cancer underscore the importance of combi-
natorial mechanisms. Evidence is accruing for temporal and spatial 
dimensions to control of gene expression, replication and repair with 
a requirement for architectural organization, assembly, integration 
and localization of regulatory machinery. Structure-function interre-
lationships are beginning to define regulatory networks that mediate 
physiological control and aberrations that are linked to the onset and 
progression of tumorigenesis.
It is now apparent that the informational content of macromol-
ecules and macromolecular complexes goes beyond DNA sequences. 
There is emerging evidence that epigenetic codes and signatures for 
components of biological control include histone subtypes, post 
translational histone modifications, DNA methylation, the subnu-
clear localization of regulatory complexes and mitotic occupancy of 
regulatory factors for proliferation, cell growth and phenotypic target 
gene loci.
The challenge we face is to configure the data from high 
throughput screens in a manner that maximizes insight into mecha- 
nisms and therapeutic targets. The scope of the strategies is rapidly 
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growing. The volume and complexities of information that is 
readily obtainable is extensive and expanding. Traditional boundaries 
between disciplines need not be an obstacle. Team approaches where 
partnerships between investigators with perspectives and skill sets 
that combine the power of genomic, proteomic, cellular, biochemical 
and molecular approaches provide the platform for novel insight 
into biological control and innovative options for cancer diagnosis 
and treatment. From a personal perspective, collaboration has been 
the most rewarding component of my career. I am confident that 
advances in understanding cancer biology and pathology through 
collaboration are more effective and meaningful than any cohort of 
individual contributions. 
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